Loading...
•
Mar 31, 2022
Vanda Q1 2022 Earnings Report
Vanda reported financial results for the first quarter ended March 31, 2022.
Key Takeaways
Vanda Pharmaceuticals reported a decrease in total net product sales to $60.2 million, a 4% decrease compared to the first quarter of 2021. The company experienced a net loss of $6.4 million compared to a net income of $8.7 million in the same period last year.
Total net product sales from HETLIOZ® and Fanapt® decreased by 4% to $60.2 million.
HETLIOZ® net product sales decreased by 6% to $37.0 million.
Fanapt® net product sales decreased by 1% to $23.2 million.
Net loss was $6.4 million compared to net income of $8.7 million in the first quarter of 2021.
Revenue by Segment
Forward Guidance
Vanda expects to achieve total revenues between $240 to $280 million, HETLIOZ® net product sales between $150 to $180 million, Fanapt® net product sales between $90 to $100 million and year-end 2022 cash greater than $440 million.
Positive Outlook
- Total revenues between $240 to $280 million.
- HETLIOZ® net product sales between $150 to $180 million.
- Fanapt® net product sales between $90 to $100 million.
- Year-end 2022 cash greater than $440 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...